Helen T. Chifotides, PhD

Srdan Verstovsek, MD, PhD, highlighted recent advancements in developing novel therapeutic strategies for myelofibrosis during SOHO 2022.

Building on the transformative impetus from the first FDA-approved JAK 1/2 inhibitor, ruxolitinib, in the clinical landscape of myeloproliferative neoplasms, we are entering a new era of multiple JAK inhibitors and other diverse classes of drugs in rapid clinical development.